How pharma could benefit from one of Congress’ signature drug pricing ideas
An insider's guide to the politics and policy of health care.
D.C. Diagnosis is STAT’s weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox.
Situational awareness: Congress’ drug pricing push is really going in pharma’s favor
If you asked me in January whether Congress would stick it to pharma this Congress, I’d say the odds were pretty darn good. Now I’m not only doubting Congress will inflict any pain on the industry, I’m starting to think the so-called reforms both Republicans and Democrats are pushing may leave the industry better off than when Congress gaveled in this January.
Hear me out: One of the big ideas Congress is talking about in earnest right now is capping what seniors can pay out of pocket each year at the pharmacy counter through Medicare
